Quintrio
Home

Stock overview

Lakefront Biotherapeutics American Depositary Shares

LKFT

Lakefront Biotherapeutics NV a biopharmaceutical company committed to improving the lives of people with severe diseases. It focuses on delivering medicines with transformational impact for patients by accelerating life-changing science and innovation in areas of high unmet need. Its pipelines includes GLPG3667, GLPG5101, and GLPG5301.

Last trade $34.77
Day change -$0.025 (-0.07%)
Day range $34.49 – $35.19
Volume 188,293
Market cap $2.29B

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

No ratio data was found for LKFT.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

No quarterly income statement data was found for LKFT.

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Lakefront Initiates New €50 Million Share Repurchase Program Following Completion of Initial Share Repurchase Program

Lakefront Biotherapeutics announced a new €50 million share repurchase program on November 16, 2026, following the completion of its initial €50 million program in October 2026. The company repurchased approximately 1.99 million shares under the initial program and believes its current share price undervalues the business. The new program will run through March 31, 2027, with Morgan Stanley acting as the independent financial intermediary.

GlobeNewswire Inc.

Lakefront start nieuw aandeleninkoopprogramma ter waarde van €50 miljoen na voltooiing van initieel aandeleninkoopprogramma

Lakefront Biotherapeutics NV has announced a new €50 million share buyback program following the completion of its initial €50 million program. The company will repurchase up to 4.6 million shares through Morgan Stanley on Euronext between November 16, 2026 and March 31, 2027. Management believes the current stock price undervalues the company and its pipeline prospects.

GlobeNewswire Inc.

Idiopathic Inflammatory Myositis Market Set for Strong Growth at 16.8% CAGR Through 2036, Driven by Rising Demand for Targeted Therapies | DelveInsight

The Idiopathic Inflammatory Myositis (IIM) market is projected to grow at 16.8% CAGR through 2036, reaching significant expansion driven by rising disease awareness, improved diagnostics, and an expanding pipeline of targeted therapies. The market was valued at USD 714 million across the 7MM in 2025, with the US accounting for 55% of the market. Multiple pharmaceutical companies are advancing investigational treatments addressing unmet medical needs in dermatomyositis, polymyositis, and inclusion body myositis.

Zacks Investment Research

Should You Buy Lakefront Biotherapeutics - Sponsored ADR (LKFT) After Golden Cross?

Lakefront Biotherapeutics (LKFT) has formed a golden cross technical pattern, with its 50-day moving average crossing above its 200-day moving average, suggesting a potential bullish breakout. The stock has risen 13.7% over the past four weeks and holds a #2 (Buy) rating on the Zacks Rank. Earnings estimates have also been revised upward, supporting the bullish outlook.

Zacks Investment Research

Lakefront Biotherapeutics - Sponsored ADR (LKFT) Upgraded to Buy: What Does It Mean for the Stock?

Lakefront Biotherapeutics (LKFT) has been upgraded to Zacks Rank #2 (Buy) based on upward trends in earnings estimates. The upgrade reflects improved earnings outlook and positions the stock in the top 20% of Zacks-covered stocks, suggesting potential for near-term price appreciation. Analysts have raised consensus estimates by 89.3% over the past three months.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.